Investor
Eshelman Ventures
- Type
- vc
- Location
- —
- Website
- —
Directory portfolio
Incyclix Bio
Selective CDK2 inhibitor developer advancing INX-315 for CDK4/6-resistant ER+/HER2- breast cancer and CCNE1-amplified solid tumors.
Investor
Incyclix Bio
Selective CDK2 inhibitor developer advancing INX-315 for CDK4/6-resistant ER+/HER2- breast cancer and CCNE1-amplified solid tumors.